title: The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
abstract: OBJECTIVE
  To compare men with prostate disease with those from the general population regarding polymorphisms in the androgen receptor gene and in the 5alpha-reductase II (SRD5A2) gene.
  
  
  METHODS
  The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
  
  
  RESULTS
  The SRD5A2 high-activity allele variants A49T AT and V89L LL were more frequent in CaP-patients compared to general population, p=0.026 and p=0.05, respectively. CaP progression was, however, independent of SRD5A2 variants. In contrary, men with GGN<23 had a higher risk of dying from the disease than their counterparts with longer repeats.
  
  
  CONCLUSIONS
  Men with CaP were more often genetically predisposed to a higher enzymatic activity in the turn over from T to DHT compared to the general population. In our population, androgen receptor genotype affected CaP outcome.
authors.affiliation: Department of Urology, Malmö University Hospital, Lund University, Wallenberg Laboratory, entrance 46, SE - 205 02 Malmö, Sweden. yvonne.giwercman@kir.mas.lu.se
authors.forename: Yvonne L
authors.initials: YL
authors.lastname: Giwercman
authors.forename: Per-Anders
authors.initials: PA
authors.lastname: Abrahamsson
authors.forename: Aleksander
authors.initials: A
authors.lastname: Giwercman
authors.forename: Virgil
authors.initials: V
authors.lastname: Gadaleanu
authors.forename: Göran
authors.initials: G
authors.lastname: Ahlgren
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000097:blood / Q000235:genetics*; D000368:Aged; D000409:Alanine; D000483:Alleles; D001120:Arginine; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D013196:Dihydrotestosterone / Q000097:blood; D018450:Disease Progression; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005973:Glutamine; D006801:Humans; D007930:Leucine; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011110:Polymorphism, Genetic; D011470:Prostatic Hyperplasia / Q000097:blood / Q000453:epidemiology / Q000235:genetics; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology / Q000235:genetics*; D011944:Receptors, Androgen / Q000097:blood / Q000235:genetics*; D012307:Risk Factors; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013548:Sweden / Q000453:epidemiology; D020079:Terminal Repeat Sequences; D013739:Testosterone / Q000097:blood; D013912:Threonine; D014633:Valine
chemical_list: D014408:Biomarkers, Tumor; D011944:Receptors, Androgen; D012738:Sex Hormone-Binding Globulin; D013196:Dihydrotestosterone; D005973:Glutamine; D013912:Threonine; D013739:Testosterone; D007986:Luteinizing Hormone; D001120:Arginine; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D007930:Leucine; D014633:Valine; D000409:Alanine